ADL
NTLA icon

Asset Dedication LLC’s Intellia Therapeutics NTLA Stock Holding History

Asset Dedication LLC’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-240
Closed -$3.08K – 1268
2026
Q1 		$3.08K Hold
240
– – ﹤0.01% 923
2025
Q4 		$2.16K Hold
240
– – ﹤0.01% 1003
2025
Q3 		$4.14K Hold
240
– – ﹤0.01% 930
2025
Q2 		$2.25K Hold
240
– – ﹤0.01% 1018
2025
Q1 		$1.71K Hold
240
– – ﹤0.01% 978
2024
Q4 		$2.8K Hold
240
– – ﹤0.01% 941
2024
Q3 		$4.93K Hold
240
– – ﹤0.01% 904
2024
Q2 		$5.37K Hold
240
– – ﹤0.01% 912
2024
Q1 		$7K Hold
240
– – ﹤0.01% 739
2023
Q4 		$7K Buy
+240
New +$6.9K ﹤0.01% 739

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Asset Dedication LLC's NTLA Position: Q2 2026 in Review

Asset Dedication LLC sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 240 shares — an estimated $3.08K sold.

Asset Dedication LLC first reported a position in NTLA in Q4 2023 and held it in 10 quarters. The position peaked at $7K in Q1 2024. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Asset Dedication LLC reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Asset Dedication LLC sold 240 Intellia Therapeutics shares in Q2 2026, an estimated $3.08K.
  • Asset Dedication LLC first reported a position in Intellia Therapeutics in Q4 2023 and held it in 10 quarters.
  • Asset Dedication LLC's Intellia Therapeutics position peaked at $7K in Q1 2024.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Asset Dedication LLC's 13F filing for Q2 2026, filed 30 Jul 2026.